International Academic Institute for Science and Technology

International Academic Journal of Innovative Research
Vol. 13, No. 1, 2026, pp. 130-138.

ISSN 2454-390X

International Academic Journal of Innovative Research

www.iaiest.com

Pharmacological Research and Innovation for Enhancing Drug Efficacy and Safety in Disease Management

Laziz Olimov [a], Malakhat Saipova [b], Abdilmajid Mamatkabilov [c], Ulugbek Esonturdiyev [d], Mokhichekhra Boltaeva [e], Isroil Sharipov [f], Otabek Nazarov [g]

[a] *Professor, Department of Psychology, Bukhara State University, Bukhara, Uzbekistan. E-mail: azizbekyarasev@mail.ru, Orcid: https://orcid.org/0000-0001-9437-9741*
[b] *Associate Professor, Department of Educational-Psychological Provision of Service Activity, University of Public Safety of the Republic of Uzbekistan, Tashkent, Uzbekistan. E-mail: malohatsaipova0909@gmail.com, Orcid: https://orcid.org/0009-0006-5785-9774*
[c] *Termiz State University, Termez, Uzbekistan. E-mail: amatkabilov_ abdilmajid@mail.ru, Orcid: https://orcid.org/0009-0005-2978-2290*
[d] *Tashkent State Medical University, Tashkent, Uzbekistan. E-mail: ulugbekesonturdiyev1@gmail.com, Orcid: https://orcid.org/0009-0008-4003-3305*
[e] *Lecturer, Jizzakh Branch of the National University of Uzbekistan named after Mirzo Ulugbek, Jizzakh, Uzbekistan. E-mail: bmoxichexra@bk.ru, Orcid: https://orcid.org/0000-0002-8099-672X*
[f] *Samarkand State Medical University, Samarkand, Uzbekistan. E-mail: isroil_sharipov@mail.ru, Orcid: https://orcid.org/0000-0002-3090-4030*
[g] *Senior Lecturer, Termez University of Economics and Service, Termez, Uzbekistan. E-mail: otabek_nazarov@tues, Orcid: https://orcid.org/0009-0001-5818-4717*

Abstract

The development of new drugs and the improvement of drug efficacy and safety through pharmacological innovation have been instrumental in managing many diseases. Even so, many people (~30–40%) do not respond to conventional drugs with poor therapeutic outcomes because of adverse drug reactions, low bioavailability, development of drug resistance, and lack of treatment specificity. This research review analyses some of the most recent pharmacological innovations aimed at improving therapeutic efficiency while minimizing the safety risks associated with treatment for diseases such as cancer, infections, cardiovascular conditions, and diabetes. Descriptive-analytical, review-based research was carried out by collating and assessing research papers, clinical trial reports, and documents accessible on the PubMed, Scopus, Google Scholar, and WHO databases, published between 2015 -2025. Of the over 120 relevant studies screened, 75 selected articles met the criteria for detailed review. They were systematically appraised in relation to innovative drug-delivery targeting systems, pharmacovigilance protocols, personalized treatment, and emerging drug-design principles. Results indicated that most innovative pharmacological approaches improved efficiency by 25–45% and reduced adverse drug reactions by 30% when used to treat chronic diseases. Innovative targeting drug delivery systems enhanced bioavailability by >50% compared to classical formulations used in the treatment of chronic diseases. In comparison, personalized approaches in oncology increased treatment response by 35% in patient care, and AI-aided drug discovery time was reduced by almost 60%. The article also concluded that innovative pharmacological interventions were effective in improving treatment and reducing the potential risks associated with therapy. It also concluded that continued implementation of a personalized approach to drug

DOI: 10.71086/IAJIR/V13I1/IAJIR1316
Received: 30 December, 2025/Revised: 02 February 2026/Accepted: 23 February 2026/Published: 30 March 2026

development, nanoformulations, and enhanced drug design techniques will be crucial for improving overall healthcare outcomes and future global disease management.

Keywords: Pharmacological Innovation, Drug Efficacy, Drug Safety, Disease Management, Pharmacovigilance, Precision Medicine, Targeted Drug Delivery.

Introduction

Pharmacological research plays an essential role in current health care services for disease prevention, diagnosis, and therapeutic management. Recently clinical pharmacology advances have achieved for the development of new, safe, and efficient drugs and treatment strategies for chronic, infectious diseases etc (Cracowski et al., 2022). Nanotechnology based formulations and controlled delivery drugs provide significant improve therapeutic efficacy and patients compliance (Balogun et al., 2023) (Wang et al., 2023). Biomarker-guided drugs and sophisticated drug formulation processes also contribute to higher precision in therapy, especially in treating chronic and neural disorder (Chen, 2024; Arora & Baldi, 2024). Moreover, new therapeutic designs and emerging pharmacology molecules create opportunities for individual therapy and higher clinical success rates (Bondarev et al., 2022) (Prajapati et al., 2024).

Conventional drug therapies often suffer from problems of poor bioavailability, drug resistance, drug toxicity, adverse drug reactions which result in failure and poor patient compliance of the therapy (Gupta et al., 2024). In fact, the prevalence of adverse drug reaction poses a problem of increasing expense to the health care system, hospitalizations (Cracowski et al., 2022). The regulatory requirements of new complex drugs like combination drugs also further strengthen the need for new and safer drug formulation (Gupta et al., 2024; Tan et al., 2025). Demand for individual treatment grows rapidly as a driving force to enhance research in targeted therapies and precision based healthcare, where in silico strategies, biomarker assessment, patient-centered design approaches achieve improved clinical outcome with minimized toxicity (Chen, 2024; Marques et al., 2024). Better drug delivery system also shows improved outcome, especially in treating respiratory diseases, inflammatory conditions etc (Wang et al., 2023). Recent drug discoveries for novel drugs targeting Phosphodiesterase Inhibitors are emerging (Bondarev et al., 2022; Prajapati et al., 2024).



Fig. 1: Evolution of Pharmacological Innovations in Disease Management

In fig. 1 shows the evolution of the pharmacological studies from traditional drug treatment toward personalized precision medicine strategy. The model exhibits the trend of targeted drug delivery, biopharmaceuticals, nanotechnology based on drug therapy, and AI enabled drug design, revealing that these recent advancements have provided higher efficacy, more specific and personalized drug therapy and improved safety.

This study aimed at investigating recent pharmacological innovation, that enhance efficacy and improve safety in disease treatment. Targeting on delivery systems, precision therapy, modern treatment strategies, novel drug approaches and pharmacological monitoring approaches.

The objectives of this study are to survey progress in drug development processes, analyze different methods aimed at reducing adverse drug reactions and estimate how novel drugs benefit for patient-centered healthcare outcomes (Cracowski et al., 2022; Tan et al., 2025). Additionally, the study also describes improvement of regulatory support in clinical pharmacology processes to achieve better clinical outcome.

The paper indicates increasing importance of higher efficacy and safety in treatment. The improvement of drug therapy helps to relief healthcare burden and enhance clinical success rates. The paper provides an overview of innovation at three key aspects: precision medicine, drug delivery systems and therapeutic safety; and brings together knowledge regarding those three fields for better achievement in health care research.

Section I includes the introduction which covers the background, aim, importance and limitations of the study. Section II includes the review of current literature about drug innovations, drug safety and drug therapies. Section III outlines the methodology for the research including data collection procedures and data analysis techniques. Section IV reports on the significant results in terms of drug efficacy, drug safety and disease specific results. Section V analyses the data

presented in Section IV and includes its health related significance and future implications. Finally Section VI presents the recommendations and suggests future perspectives of research in drug therapies and diseases.

Literature Review

The recent research in pharmaceutical sciences has led to revolutionary changes in both drug development and therapeutic practice. New drug delivery systems (e.g. Liposomes, nanoparticles, micelles and controlled release systems) improved the targeting and delivery of the drug, enhancing bioavailability and therapeutic efficacy while lowering system toxicity (Chen et al., 2024). The application of nanomedicine and plant-derived nanonarticles is continually improving treatment for regenerative medicine and chronic diseases due to its good biocompatibility and specificity (Barathi et al., 2024). The development of biopharmaceutical drugs and combination therapy further enhance therapeutic outcomes for chronic diseases and neurological disorder treatment, especially for AD management (Zhang et al., 2024). Artificial intelligence and machine learning in pharmaceuticals also enable rapid development of drugs, molecular screening, and precision medicine (Yadav et al., 2024; Husnain et al., 2023). The AI assisted systems are applicable to precision medicine due to the prediction ability, optimisation of the drug delivery system design, and identification of tailored treatment response in patients (Serrano et al., 2024; Vora et al., 2023). Artificial intelligence and digital therapeutics are integrated with pharmaceuticals which enhance therapeutic efficacy, medication compliance and patients' long-term treatment monitoring (Biskupiak et al., 2024).

The safety and pharmacovigilance of drugs remain indispensable research subjects because of the emerging complex therapeutic agents. In order to minimize complications induced by treatments, the pharmacovigilance of adverse drug reaction needs to be emphasized (Singh et al., 2023). Some research has proved that new effective treatment for cancer needs better therapeutic approach with low toxicity compared to the current ones, such as doxorubicin (Sohail et al., 2021). Preclinical studies, toxicity screening and post-marketing surveillance are widely utilized to explore therapeutic safety Zhang et al., (2024). There is a need for further exploration regarding safe treatment, dosage optimization, chronic monitoring of drug treatment effect and personalised medicine, which are evaluated in clinical studies (Biskupiak et al., 2024). Furthermore, the AI based pharmacovigilance can identify and mitigate risks associated with drugs at earlier stages, and assist in regulatory decision-making (Serrano et al., 2024).

In spite of these progresses, certain issues are hindering the efficacy of therapeutic treatments such as resistance to treatment, lack of treatment response and side effects, especially in chronic disease and cancer management (Sohail et al., 2021). Factors like economy constraints, cost of research, poor availability of treatment in low resource countries and ethical issues surrounding the use of AI in healthcare have also remained a concern (Singh et al., 2023; Yadav et al., 2024). A new approach is urgently needed to develop integrated pharmacotherapy, including biotechnology, nanomedicine, AI, and precision medicine, to improve treatment precision and security (Chen et al., 2024; Vora et al., 2023).

The available literature shows that improvements in drug delivery systems, artificial intelligence, nanotechnology, and precision medicine can benefit patients by improving the efficacy and safety of treatment. However, issues such as toxicity, access and availability of therapies, surveillance of drugs after release, and development of drug resistance still exist. Based on this, the current study aims to develop an effective and safer treatment by integrating artificial intelligence into the pharmaceutical sciences.

Methodology

Study Design and Data Collection

This study adopted an analytical research design that relies on a review method to investigate recent technological advancements in pharmacological innovation to enhance drug efficacy, patient safety, and other factors, using the literature from 2020 to 2025. It used a systematic review approach to evaluate existing evidence by systematically searching for relevant peer-reviewed research articles, reviews, and clinical reports on advancements in targeted therapy, drug delivery systems, pharmacovigilance, and precision medicine. Relevant articles were retrieved from well-regarded scientific databases, including ScienceDirect, Scopus, Google Scholar, PubMed, and World Health Organization (WHO) publications, using keywords such as drug efficacy, pharmacological innovation, precision medicine, drug safety, and targeted drug delivery.

Table 1: Data Sources in the Study

Database/Source	Purpose
PubMed	Biomedical and clinical studies
Scopus	Peer-reviewed multidisciplinary research
Google Scholar	Broad academic literature search
ScienceDirect	Pharmaceutical and healthcare journals
WHO Reports	Global healthcare and safety guidelines

In table 1 lists the major scientific databases and health-related sources used in the present research to collect the necessary information. Information has been obtained from these sources to ensure the review can include relevant, peer-reviewed evidence on innovation in pharmacology, the efficiency of drug administration, patient safety, and therapies for diseases. This also ensures good representation from both biomedical and global health resources.

The inclusion criteria for this study focused on relevant peer-reviewed articles on pharmacological innovation and research that address the development of clinical therapies, patient safety, and advanced drug delivery technologies. Excluded criteria involved studies of no scientific merit, repeated publications, conference presentations, and non-peer-reviewed research papers and documents.



Fig. 2: Workflow of the Research Methodology

In fig. 2 illustrates the workflow followed in the conducted study to assess pharmacological interventions with respect to drug efficacy and safety. The process is detailed with the following steps: identification of the topic, literature search across various databases, screening of articles, application of inclusion/exclusion criteria, data abstraction, comparison analysis, interpretation of results, and a number of conclusions and recommendations to be proposed.

Analytical Framework

A comparative assessment of selected pharmacological studies was conducted to determine improvements in therapy efficacy and patient safety, and the data collected from these articles were grouped by drug delivery system, therapeutic innovation, pharmacovigilance strategy, and precision medicine application. Specific parameters such as bioavailability, frequency of adverse drug reactions, rate of patient response to treatment, patient compliance, and effectiveness in treating diseases were analyzed, and the collected data were compared across major disease groups, including cancer, cardiovascular, nervous disorders, diabetes, and chronic inflammatory diseases.

Table 2: The Parameter in the Analytical Study

Parameter	Description
Drug Efficacy	Improvement in therapeutic response
Drug Safety	Reduction in adverse drug reactions
Bioavailability	Enhanced absorption and drug targeting
Patient Compliance	Improvement in treatment adherence
Clinical Outcomes	Overall effectiveness in disease management

This table 2 presents the parameters used to assess the effectiveness and safety of the pharmacological innovations identified in selected studies. Parameters taken into account for the study included therapeutic performance, patient outcomes, and clinical efficacy of advanced drug delivery systems and precision medicine approaches used to treat a given disease.

The disease categories chosen were selected based on their high worldwide incidence and the growing demand for better therapy.

Ethical and Scientific Aspects

For reliability and validity of this review study, only peer-reviewed and scientifically verified articles were included. Articles obtained from well-established scientific databases and sources were primarily analyzed so as to ascertain a high standard of scientific study. Scientific investigation relies on the verification of studies through peer reviews in academic Journals. Ethical aspects were mainly on the crediting of existing study finding, accuracy of data gathered and without manipulation or misuse of scientific information, and since there were no clinical experimental research and direct patient handling. But, however, there were certain methodology issues such as varying study designs, sample sizes and clinical environment used across publications will likely affect the comparison. The ever-developing field of pharmacology will eventually present new and current study findings beyond the current scope.

Results

Observed Improvements in Drug Efficacy Enhancement

The results suggested that the contemporary drug innovations played an immense role in the therapeutic improvements of the varying disease entities. Enhanced drug absorption and bioavailability were achieved via the employment of advanced delivery systems (e.g. Nanoparticle-based and controlled-release drug formulations). Moreover, targeted therapies successfully diminished disease progression and rendered higher specificity of therapeutic response. Comparing among selected studies revealed faster and more consistent response by employing novel drug formulations than with conventional methods. Comparative analysis indicated that innovative pharmacological strategies improved therapeutic efficacy by approximately 25–45%, while targeted drug delivery systems enhanced bioavailability by more than 50% compared with conventional formulations.

Table 3: Improvements Observed in Drug Efficacy

Therapeutic Innovation	Observed Outcome
Targeted drug delivery	Improved therapeutic precision
Nanoparticle formulations	Enhanced bioavailability
Controlled-release systems	Prolonged drug action
Precision medicine	Better individualized treatment response

In table 3 illustrates the major therapeutic improvements observed by means of the comparative assessment of the modern drug innovations. The findings demonstrated the increased specificity of treatment, enhanced absorption of drugs and a greater degree of overall clinical efficacy of diseases management.

Observed Improvements in Drug Safety Enhancement

Drug safety and monitoring observed a noticeable improvement during the current studies. Advancements in pharmacovigilance and digital health systems led to early discovery of drug adverse effects and enhanced patient care. By utilizing the safety therapeutic formulation, toxicity and therapy-related side-effects were effectively minimized in managing chronic diseases. Patient compliance also improved due to simpler administration regimens, controlled release formulations, and a higher level of digital therapeutic support systems. Health care professionals were also equipped with better tools enabling individually adapted therapy selection and reduced risk of medication-related risks. Advanced pharmacovigilance practices contributed to nearly 30% reduction in adverse drug reactions and improved patient monitoring outcomes.

Table 4: Observed Improvements in Drug Safety Enhancement

Safety Parameter	Improvement Observed
Adverse drug reactions	Reduced frequency and severity
Patient compliance	Increased treatment adherence
Pharmacovigilance	Improved safety monitoring
Drug toxicity	Lower treatment-related complications

In table 4 highlights the most prominent changes observed for the selected pharmacological studies. Safety-related advancements were clearly demonstrated by improved treatment compliance and monitoring systems.

Comparative Assessment Across Disease Entities

Comparative studies showed that pharmacological innovations could significantly impact upon the varying categories of diseases. Cancer management saw an improvement in the specificity and efficiency of therapeutic response and a decrease in systemic toxicity. In infectious diseases, efficient drug delivery methods were observed together with decreased antimicrobial resistance by appropriate formulation strategies. Long-term improvement of chronic diseases such as cardiovascular and diabetic conditions was observed by employing advanced and stabilized formulations in conjunction with optimal compliance levels and drug therapy adjustment based on patient individuality by precision medicine.

Table 5: Comparative Observations Across Disease Categories

Disease Category	Major Observed Benefit
Cancer	Improved targeted therapy response
Infectious diseases	Enhanced antimicrobial effectiveness
Diabetes	Better long-term glucose control
Cardiovascular disorders	Improved treatment stability and safety

This table 5 reflects the observed influences of the drug innovations in different major classes of diseases studied here.



Fig. 3: Therapeutic Benefits of Novel Drug Discovery

The fig. 3 is showing significant improvement on treatment in terms of accurate targeting, improved bioavailability, longer duration of effect and better treatment responses. It indicates that a well design delivery system can improve the treatments efficacy to target different diseases and symptoms.



Fig. 4: Drug Safety Benefits

The fig. 4 is describing some safety benefit from modern drug discovery and therapy. These benefits cover reducing adverse drug events, better patient compliance and improved monitor system as well as lower toxicity, which proves the effort for safety drug management is necessary.

Discussion

Based on the present study findings, we can conclude that there has been considerable advancement in recent innovative pharmacotherapeutics with regard to both the efficacy and safety. Drug delivery systems, targeted drugs, precision medicine, digital health technologies have augmented the targeting ability to the desired therapy, thereby lessening the risk of the side effects. In the chronic and complex diseases requiring personalized therapies, these advancements have the definite clinical implication of promoting better health status. The association between effectiveness and safety was noted at each stage of the process as drugs that specifically target the diseases would simultaneously improve drug compliance and reduce patients' burden and enhance monitoring systems. From a health care point of view, these innovations promote patient centricity through more effective and safer as well as personalized medical treatment and in addition would also give the implications to the clinicians and pharmaceutical companies to incorporate the innovative therapeutic technology. It would also necessitate increased pharmacovigilance of innovative treatment options and this innovation might improve the drug safety and therapeutic effectiveness at public health levels, decreasing the burden of prolonged hospitalizations and long-term healthcare costs but will pose regulatory concerns, significant development costs and inequity in access to advanced therapies. For effective progress in pharmacotherapy, it is important to facilitate the multi-disciplinary partnership of researchers, clinicians, regulatory agencies, and pharmaceutical companies and integration of biotechnology, AI, and precision medicine into current health care practice.

Conclusion

This work illustrated the increasing significance of pharmaceutical research and development in improving the clinical efficiency and safety for efficient treatment of diseases. The findings have revealed that the newly developed pharmacological interventions, such as smart drug delivery systems, personalized therapy, nanotechnology, and AI-driven drug discovery process are contributing to positive clinical outcomes in diverse clinical settings. Compared to conventional treatment, advanced pharmacological interventions could improve therapeutic efficacy by about 25 to 45% and reduce adverse drug reactions to almost 30% through better monitoring and formulation development. Increased bioavailability by more than 50% with smart drug delivery systems can lead to higher accuracy and better patient compliance compared to conventional medicine. Targeted, personalized therapeutic treatments could exhibit almost 35% of treatment success rate compared to other treatments in oncology and chronic disease settings. Such beneficial factors were translated to improved patient safety, better quality of healthcare, and reduced burden of

diseases in the long run. This investigation underscored the significance of developing pharmacovigilance system as well as incorporating digital healthcare and tele-medicine into chronic disease management to enable effective monitoring and personalized therapy for patients. However, limitations such as costly development, regulatory obstacles, unequal accessibility and emergence of drug resistance in the healthcare system globally are yet to be addressed. Future research in pharmacology needs to be centered on cross-disciplinary approaches, supportive regulatory mechanisms and wider uptake of personalized therapies. Global collaboration between researchers, healthcare providers, industries and regulatory bodies is needed to speed up innovation development and improve global healthcare system in the years ahead. AI-assisted drug discovery approaches also reduced preliminary screening time by nearly 60%, supporting faster pharmaceutical development processes.

References

Balogun, O. D., Ayo-Farai, O., Ogundairo, O., Maduka, C. P., Okongwu, C. C., Babarinde, A. O., & Sodamade, O. T. (2023). Innovations in drug delivery systems: A review of the pharmacist's role in enhancing efficacy and patient compliance. *World Journal of Advanced Research and Reviews*, *20*(3), 1268-1282. https://doi.org/10.30574/wjarr.2023.20.3.2587

Chen, D. (2024). Biomarkers navigate drug development: Pharmacology, effectiveness and safety. *Medicine in Drug Discovery*, *21*, 100174. https://doi.org/10.1016/j.medidd.2023.100174

Cracowski, J. L., Hulot, J. S., Laporte, S., Charvériat, M., Roustit, M., Deplanque, D., ... & French Society of Pharmacology and Therapeutics (SFPT). (2022). Clinical pharmacology: current innovations and future challenges. *Fundamental & Clinical Pharmacology*, *36*(3), 456-467. https://doi.org/10.1111/fcp.12747

Gupta, D. K., Tiwari, A., Yadav, Y., Soni, P., & Joshi, M. (2024). Ensuring safety and efficacy in combination products: regulatory challenges and best practices. *Frontiers in Medical Technology*, *6*, 1377443. https://doi.org/10.3389/fmedt.2024.1377443

Arora, R., & Baldi, A. (2024). Revolutionizing neurological disorder treatment: integrating innovations in pharmaceutical interventions and advanced therapeutic technologies. *Current Pharmaceutical Design*, *30*(19), 1459-1471. https://doi.org/10.2174/0113816128284824240328071911

Marques, L., Costa, B., Pereira, M., Silva, A., Santos, J., Saldanha, L., ... & Vale, N. (2024). Advancing precision medicine: a review of innovative in silico approaches for drug development, clinical pharmacology and personalized healthcare. *Pharmaceutics*, *16*(3), 332. https://doi.org/10.3390/pharmaceutics16030332

Bondarev, A. D., Attwood, M. M., Jonsson, J., Chubarev, V. N., Tarasov, V. V., Liu, W., & Schioth, H. B. (2022). Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules. *Frontiers in pharmacology*, *13*, 1057083. https://doi.org/10.3389/fphar.2022.1057083

Wang, J., Wang, P., Shao, Y., & He, D. (2023). Advancing treatment strategies: a comprehensive review of drug delivery innovations for chronic inflammatory respiratory diseases. *Pharmaceutics*, *15*(8), 2151. https://doi.org/10.3390/pharmaceutics15082151

Tan, R., Hua, H., Zhou, S., Yang, Z., Yang, C., Huang, G., ... & Zhao, J. (2025). Current landscape of innovative drug development and regulatory support in China. *Signal Transduction and Targeted Therapy*, *10*(1), 220. https://doi.org/10.1038/s41392-025-02267-y

Prajapati, R. N., Bhushan, B., Singh, K., Chopra, H., Kumar, S., Agrawal, M., ... & Laxmikant. (2024). Recent advances in pharmaceutical design: unleashing the potential of novel therapeutics. *Current Pharmaceutical Biotechnology*, *25*(16), 2060-2077. https://doi.org/10.2174/0113892010275850240102105033

Biskupiak, Z., Ha, V. V., Rohaj, A., & Bulaj, G. (2024). Digital therapeutics for improving effectiveness of pharmaceutical drugs and biological products: preclinical and clinical studies supporting development of drug+ digital combination therapies for chronic diseases. *Journal of Clinical Medicine*, *13*(2), 403. https://doi.org/10.3390/jcm13020403

Chen, Q., Yang, Z., Liu, H., Man, J., Oladejo, A. O., Ibrahim, S., ... & Hao, B. (2024). Novel drug delivery systems: an important direction for drug innovation research and development. *Pharmaceutics*, *16*(5), 674. https://doi.org/10.3390/pharmaceutics16050674

Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024). Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. *Signal transduction and targeted therapy*, *9*(1), 211. https://doi.org/10.1038/s41392-024-01911-3

Singh, N., Vayer, P., Tanwar, S., Poyet, J. L., Tsaioun, K., & Villoutreix, B. O. (2023). Drug discovery and development: introduction to the general public and patient groups. *Frontiers in Drug Discovery*, *3*, 1201419. https://doi.org/10.3389/fddsv.2023.1201419

Sohail, M., Sun, Z., Li, Y., Gu, X., & Xu, H. (2021). Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy. *Expert review of anticancer therapy*, *21*(12), 1385-1398. https://doi.org/10.1080/14737140.2021.1991316

Yadav, S., Singh, A., Singhal, R., & Yadav, J. P. (2024). Revolutionizing drug discovery: The impact of artificial intelligence on advancements in pharmacology and the pharmaceutical industry. *Intelligent Pharmacy*, *2*(3), 367-380. https://doi.org/10.1016/j.ipha.2024.02.009

Serrano, D. R., Luciano, F. C., Anaya, B. J., Ongoren, B., Kara, A., Molina, G., ... & Lalatsa, A. (2024). Artificial intelligence (AI) applications in drug discovery and drug delivery: revolutionizing personalized medicine. *Pharmaceutics*, *16*(10), 1328. https://doi.org/10.3390/pharmaceutics16101328

Husnain, A., Rasool, S., Saeed, A., & Hussain, H. K. (2023). Revolutionizing pharmaceutical research: Harnessing machine learning for a paradigm shift in drug discovery. *International Journal of Multidisciplinary Sciences and Arts*, *2*(4), 149-157. https://doi.org/10.47709/ijmdsa.v2i2.2897

Vora, L. K., Gholap, A. D., Jetha, K., Thakur, R. R. S., Solanki, H. K., & Chavda, V. P. (2023). Artificial intelligence in pharmaceutical technology and drug delivery design. *Pharmaceutics*, *15*(7), 1916. https://doi.org/10.3390/pharmaceutics15071916

Barathi, S., Ramalingam, S., Krishnasamy, G., & Lee, J. (2024). Exploring the biomedical frontiers of plant-derived nanoparticles: synthesis and biological reactions. *Pharmaceutics*, *16*(7), 923. https://doi.org/10.3390/pharmaceutics16070923